A new approach to cancers of the lung and esophagus shows promise for less invasive, more targeted treatment. SPIE Photonics Europe - http://spie.org/epe Brian C. Wilson is Professor of Medical Biophysics and Head of the Division of Biophysics and Bioimaging at the Ontario Cancer Institute/University of Toronto since 1993. A graduate in Natural Sciences from Glasgow University, Scotland, he worked at the Institute of Cancer Research/Royal Marsden Hospital in London and then in Australia before moving to McMaster University/Hamilton Cancer Center, Canada in 1981, where he initiated a research program in photodynamic therapy (PDT). This developed into a broad program in biophotonics, including fundamental studies in optical biophysics and translational/clinical projects in early cancer detection, PDT for brain, GI and prostate cancer, fluorescence image-guided surgery, and new technologies for molecular pathology. Recently, this program has expanded to the use of nanoparticles as image contrast agents for endoscopy and molecular pathology. Wilson has published over 400 scientific papers. He has held Visiting Professor positions at Harvard University/MGH and University of Sao Paulo, Brazil and is currently Professor-at-Large, Institute of Advanced Studies, University of Western Australia. He serves on numerous national and international research advisory committees, is a consultant to several Canadian, European and US biophotonics companies and is co-founder of three bioimaging/therapeutics companies.
Views: 343 SPIETV
A new tool in the fight against Barrett's Esophagus shows promise. A recent study published in the New England Journal of Medicine indicates that radiofrequency ablation, or RFA, is helping those whose chronic acid reflux has turned into Barrett's Esophagus.
Views: 8678 UNC Health Care
upi.com reports that A breath test to detect stomach and esophageal cancers shows promise, researchers say. The test measures five chemicals in the breath. It was 85 percent accurate in detecting these cancers in more than 300 patients, the new study found. Each year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide. Both tend to be diagnosed at a late stage and the five-year survival rate for the two cancers is 15 percent, the researchers said. http://www.upi.com/Health_News/2017/01/31/Can-breath-test-detect-stomach-cancers-earlier/9691485882741/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Views: 106 Wochit News
The Cytosponge is a tiny sponge on a string which expands in the human stomach. When it is pulled out, the expanded sponge collects cells along your food pipe. This can be a detector for oesophageal cancer. The 5-year survival rate for this cancer is just 18%, mostly due to late diagnosis. The sponge is now being trialled at around 150 GP practices in the UK. -------------------------------------------------- Follow BI UK on Twitter: http://bit.ly/1Nz3jG3 Follow BI UK On Facebook: http://bit.ly/1VWDkiy Read more: http://uk.businessinsider.com/?IR=C -------------------------------------------------- Business Insider UK is the largest business news site for British readers and viewers in the UK. Our mission: to tell you all you need to know about the big world around you. The BI UK Video team focuses on business, technology, strategy, and culture with an emphasis on unique storytelling and data that appeals to the next generation of leaders – the digital generation.
Views: 4963 Tech Insider
Tom Holste learned he had Barrett's Esophagus (esophageal cancer) after suffering from severe acid reflux and heartburn for more than a decade. He went through multiple treatments for his Barrett's Esophagus but it wasn't until he met Marcia Canto, M.D., Director of Clinical Research, Division of Gastroenterology, at Johns Hopkins Medicine that he was cured. Dr. Canto advised a plan to save his esophagus through piecemeal resection and ablation. For more information, visit http://www.hopkinsmedicine.org/gastroenterology_hepatology/
Views: 3637 Johns Hopkins Medicine
Esophageal cancer affects over 450,000 people worldwide. In the United States, approximately 17,000 people are newly diagnosed each year, while some 16,000 current patients will succumb to the disease. An esophagectomy (removal of all or part of the esophagus) is a common surgical procedure for the treatment of esophageal cancer. The esophagus is reconstructed by repositioning the stomach or connecting it to a removed section of the intestinal track, creating a "mock" esophagus. However, esophagectomies are complex and carry high risk, with a 19% 90-day mortality rate. Problems resulting from esophagectomies include pulmonary complications, leaks at the junction of the reconstructed esophagus, gastroesophageal reflux, and dumping syndrome. In order to improve the surgical outcome of these procedures and enhance patient quality of life, new and better tools are needed for esophageal reconstruction. Biostage is working on a new regenerative technology to address esophageal cancer through their pioneer Cellframe Technology. Two weeks before the surgery, stem cells are harvested from patient abdominal adipose tissue and allowed to incubate with a biocompatible esophageal implant. These cells interact and adhere to the implant and are able to respond to signals for regeneration once inside the patient, potentially restoring both the structural and functional integrity of the esophagus. These new approaches to organ implants could revolutionize resectional surgery by providing patients with functional replacements derived from their own cells. Website: www.xvivo.net Follow Us: Google+ http://bit.ly/1maXxwD Facebook http://on.fb.me/1gJJvml Twitter https://twitter.com/XVIVO
Views: 3022 XVIVO Scientific Animation
Course Director, Robert L. Ferris, MD, PhD, discusses immunotherapy in head and neck cancer in this CME/CE/CPE activity titled "Understanding the Impact of Immunotherapy on Head and Neck Cancer: A Look at the Science, Practice, and Future of Multimodal Treatment." For the full presentation, downloadable Practice Aids and slides, complete CME/CE/CPE information, and to apply for credit, please visit us at http://www.peerview.com/RBS865. CME/CE/CPE credit will be available until November 1st, 2018.
Views: 654 PeerView Oncology
Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.
Views: 539 OncLiveTV
Mayo Clinic is the only medical center in Arizona to provide a new treatment for select patients with gastrointestinal reflux disease, or GERD, commonly known as heartburn. The treatment involves a minimally invasive surgical procedure where a small ring of magnetic beads is inserted around the end of a patient's esophagus. Swallowing temporarily breaks the magnetic bond between the beads so that food can enter the stomach. Magnetic attraction then causes the beads to close so acid can't find its way up into the esophagus. "This procedure shows promise as an option for patients who do not respond well to lifestyle changes or those who want an alternative to medication,"says Kristi Harold, M.D., General Surgery, Mayo Clinic in Arizona. "Left untreated, GERD can lead to Barrett's esophagus, which increases risk for esophageal cancer."
Views: 3226 Mayo Clinic
Yelena Y. Janjigian, MD; Zev A. Wainberg, MD; and Alan P. Venook, MD, provide considerations for the upfront treatment approaches in unresectable or metastatic gastric and GEJ cancers.
Views: 240 OncLiveTV
Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the addition of checkpoint inhibitors to the treatment landscape for patients with gastric and esophageal cancer and potential combinations being investigated.
Views: 71 OncLiveTV
In this presentation from the ESMO 19th World Congress on Gastrointestinal Cancer, Dr. Ian Chau utilizes a series of case discussions to elucidate whether neo-adjuvant or adjuvant therapy is the most optimal approach for the treatment of gastric cancer. Earn CME credit for related activities at http://elc.imedex.com © 2017 Imedex, LLC.
Views: 530 ImedexCME
Please watch: "How to earn money online, make money online easy captcha entry typing from home" https://www.youtube.com/watch?v=3rCoiTV8-PA --~-- Cure All Types of Cancer and Any Stage of Cancer Completely. Excellent Cancer Treatment and curable medicine in Shimoga Karnataka. Its cured naturally, we need to identify the symptoms and check the area throat, cervical, stomach, oral then give the report to them.
Views: 386 Vijayan Tech
Zev A. Wainberg, MD; Alan P. Venook, MD; and Yelena Y. Janjigian, MD, consider the value of immunotherapy in treating advanced or metastatic gastric and GEJ cancers, including novel approaches with pembrolizumab.
Views: 253 OncLiveTV
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Barbara A. Burtness discusses current and future strategies for esophageal cancer. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7228 © 2016 Imedex, LLC.
Views: 896 ImedexCME
Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.
Views: 232 OncLiveTV
Researchers in Singapore have identified two new sub-types of gastric cancer. This is based on a new way of classifying stomach cancers, using the patients' genetic make-up. First published Aug 2 2011. Copyright © 2011 MediaCorp Pte Ltd. All Rights Reserved.
Views: 100 NewsSingapore
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series that provides educational discussions on controversial areas in the management of gastrointestinal malignancies. Join us as nationally-recognized thought leaders take opposing sides on topics of clinical interest, and present updates in standards of care. In this presentation, Dr. Eric Van Cutsem argues that chemotherapy alone is the preferred threatment for pre-op esophagus and GE junction cancer patients. © 2015 Imedex, LLC.
Views: 136 ImedexCME
In this clinical case, Dr John Morris, Consultant Gastroenterologist at Glasgow Royal Infirmary, uses Hemospray to treat an esophageal bleed post laser therapy Hemospray® Endoscopic Hemostat INSTRUCTIONS FOR USE (IFU) https://www.cookmedical.com/data/IFU_PDF/12898_0318.PDF MORE INFO https://www.cookmedical.com/products/35a4a7f2-867b-4c81-a983-44ea06277852/ INTENDED USE This device is used for hemostasis of nonvariceal gastrointestinal bleeding. NOTE: HEMOSPRAY INTENDED USE IS NOT THE SAME FOR ALL REGIONS. NOTES Do not use this device for any purpose other than stated intended use. Store in a dry location, away from temperature extremes. Use of this device is restricted to a trained healthcare professional. DEVICE DESCRIPTION Hemospray is an inert, bentonite powder developed for endoscopic hemostasis. The powder is delivered by use of a carbon dioxide powered delivery system and through a catheter inserted through the working channel of an endoscope which provides access to the site of the bleed. Each device contains approximately 20g of powder. CONTRAINDICATIONS Those specific to primary endoscopic procedure to be performed in gaining access to desired target site. Also contraindicated in patients who have gastrointestinal fistulas, are suspected of having a gastrointestinal perforation, or are at high risk of gastrointestinal perforation during endoscopic treatment. WARNINGS Keep catheter tip at least 1 cm away from bleeding site to minimize risk of embolization. Hemospray has not been approved for use in pediatric populations, no safety or effectiveness data exists and would be considered off-label usage, to do so is at the professional risk of the surgeon/healthcare professional. Patients with gastrointestinal bleeding that are on antithrombotic medication may be at an increased risk of rebleeding. Follow the relevant clinical guidelines for management of antithrombotic agents for endoscopic procedures. This device is designed for single use only. Attempts to reprocess, resterilize, and/or reuse may lead to device failure and/or transmission of disease. If package is opened or damaged when received, do not use. Visually inspect with particular attention to kinks, bends and breaks. If an abnormality is detected that would prohibit proper working conditions, do not use. Please notify Cook for return authorization. PRECAUTIONS For best results, Hemospray must be delivered to the source of bleeding. Ensure gastrointestinal lumen is not distended because Hemospray adds volume in excess of insufflation volumes during procedure. Closely monitor bowel distension and balance insufflation and Hemospray volumes as necessary. Use of more than (3) Hemospray devices per patient may result in impaction in colon and is not recommended. Product contains 16 g CO2 cartridge. Contents under pressure. Do not puncture or heat above 120° F/ 49° C. Do not inhale or discharge towards face/body. Keep CO2 dispenser and cartridge out of reach of children. Hemospray is inert and non-toxic. As a granular material, unintentional exposure to the powder may cause potential irritation to the skin, eyes and lungs. In the event of unintended exposure to the powder refer to the following First Aid measures: Skin: Wash with soap and water until clean. Eyes: Flush with water until irritation ceases. Inhalation: Move to area free from powder. If symptoms of irritation persist, contact physician. Inhalation may aggravate existing respiratory illness. Refer to package label for minimum channel size required for this device. All endoscopic hemostatic therapies, including Hemospray, have an associated risk of rebleeding, particularly in situations where the cause of bleeding is an unresolved underlying disease. After hemostasis has been achieved, monitor patients for rebleeding per the relevant Clinical Guidelines. Although not seen in clinical practice, there remains a theoretical risk of aspiration of Hemospray powder resulting in respiratory complications. It is prudent to restrict the use of Hemospray to 5 cm below the UES. PROCEDURAL PRECAUTIONS Like other modalities, Hemospray may not be effective for all types of bleeds. Gastrointestinal bleeding may exacerbate existing comorbidities, increasing the potential for adverse events including patient mortality.
Views: 150 Cook Medical Endoscopy Channel
Zev A. Wainberg, MD from the University of California Medical Centre, CA, USA summarises the results of the KEYNOTE-059 Update study in patients with pre-treated metastatic gastric cancer. Presented at the ESMO 2017 Congress in Madrid, Spain, Pembrolizumab has shown a promising response rate. The expected survival of patients with metastatic gastric cancer is less than one year and very few new drugs have been approved for this disease in the past decade. The phase II KEYNOTE-059 is one of the largest studies to investigate immunotherapy in recurrent or metastatic gastric cancer and is an important study for gastric cancer, where new treatments are desperately needed. Watch the video to find out more. Recorded during the ESMO 2017 Congress.
Views: 217 VJOncology
Dr. Mubin Syed discusses his study on gastric artery embolization as a potentially new treatment for obesity. The study was presented at RSNA 2015.
Views: 215 RSNAMedia
When the doctor tells you your child has cancer, your world stops. But remarkable advances have occurred in molecular and cell biology over the past 50 years. New technologies such as gene and cell therapies hold great promise, especially for the treatment of rare diseases. Here, learn about a recently approved new therapy for a rare childhood cancer—and what the future may hold—from Peter Marks, M.D., Director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. For more information: https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Events/ucm593077.htm
Views: 485 USFoodandDrugAdmin
Squamous cell carcinoma and adenocarcinoma are the two major histologic types of non-small cell lung cancer. ... However, differences in biological aggressiveness between squamous cell carcinoma and adenocarcinoma of the lung are not well understood.Squamous cell carcinoma that develops on the skin is usually caused by spending too much time in the sun over the course of your life. This type of skin cancer tends to grow and spread more than basal cell cancers. In rare cases, it may spread to the lymph nodes.I've read here about the difference in reaction to the newer drugs and ... differences between squamous cell and adenocarcinoma would you highlight? ... believe and have observed that squamous cell lung carcinomas are ...The patients with squamous cell carcinomas, however, were in the median about Official Full-Text Paper (PDF): Differences Between Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Are Adenocarcinoma and Squamous Cell ...Adenocarcinoma: About 40% of lung cancers are adenocarcinomas. ... Squamous cell (epidermoid) carcinoma: About 25% to 30% of all lung ...Comprehensive genomic profiling (CGP) shows promise in advanced esophageal squamous cell carcinomas (ESCC) and adenocarcinoma ...Since the incidence of adenocarcinoma (AC) of the uterine cervix has ... cancer, 645 of whom had squamous cell carcinoma (SCC) and 168 AC, including .... there was no significant difference in the outcome between different ...There can be some overlap in the staining between adenocarcinoma and squamous cell carcinoma, however it is exceedingly rare for ...
Views: 103 HealthCare Tips
http://barretts-esophagus-cure.info-pro.co Barrett's Esophagus Cancer, Barrett's Esophagus Hereditary, Barrett's Esophagus Biopsy Results. WHAT’S YOUR HEALTH WORTH TO YOU? Whether you’re personally suffering with Barrett’s, or you’re concerned about helping a loved one, ‘How I Cured My Barrett’s Esophagus’ was written and priced affordably to help you. You can instantly begin a new treatment today because I’ve painstakingly combined, safety tested, and proven techniques that can potentially begin to eliminate your symptoms… and the damage to your esophagus. I cannot make any claims or promises that what worked for me will work for you. However, I can say that countless others have benefited and reclaimed their lives by using the remedies outlined in my book. Imagine the possibilities if you. Stopped Esophageal Destruction Before it Transformed Into You-Know-What Altered Your Fate Now By Making a Few Simple Tweaks to Your Daily Routine Stopped the Pain. Stopped the Worrying. Stopped the Fear of the Future… And Finally Got Back to Enjoying the Healthy (And Not So Healthy) Foods You Love! How I Cured My Barrett’s Esophagus Click Here http://barretts-esophagus-cure.info-pro.co https://www.youtube.com/watch?v=kZRMj1nb5lw http://barrettsesophaguscure.blogspot.com/ Subscribe to our channel Barrett's Esophagus Cancer, Barrett's Esophagus Hereditary, Barrett's Esophagus Biopsy Results
Views: 232 Barrett's Esophagus Diet
SUBSCRIBE to NewsBreaker's YouTube Channel: http://bit.ly/YgsSEg A combination of two immunotherapy drugs was found to stop cancer spread in 58% of subjects. It works by turning on the immune system to inhibit cancer growth. FACEBOOK: https://www.facebook.com/newsbreaker.ora TWITTER: http://twitter.com/newsbreaker TUMBLR: http://nboratv.tumblr.com/ CHECK OUT our homepage: http://www.ora.tv/newsbreaker
Views: 214 NewsBreaker
Hey friends! So this is going to be a multiple part series of videos I upload to my channel. I know my life is going to sound fake by the end of this but I promise I wouldn’t lie about any of it lmao. I hope you all stay tuned to hear about the things I have gone through, and hopefully I can help somebody else going through similar situations.
Views: 1912 Gabrielle Webb
Dr Thomas Lodi Inspiring Patient Story https://www.anoasisofhealing.com/dr-thomas-lodi-patient-story/ http://www.anoasisofhealing.com/video-disclaimer/ This is my personal story of my mother that was a patient of Dr. Thomas Lodi as well as An Oasis Of Healing. My name is Russ Curran. I brought my mom to An Oasis Of Healing to be treated by Dr. Thomas Lodi and also his integrative alternative cancer therapies that take place at his recovery facility. I wish to supply some background on my mother so you understand why we chose Dr. Thomas Lodi's alternative cancer recovery center in Mesa, AZ. Back in 2000, my mother was identified with lung cancer and I was frightened because I was afraid of cancer and knew little about it. As a result of that concern I had, and the concern my mom had and the rest of my family members, we unfortunately listened to her physicians and went through the conventional cut, burn and poison technique of treatment, better referred to as surgery, radiation and also chemotherapy. The critical turning point for me back in 2000 and why I inevitably wound up at Dr. Lodi's An Oasis Of Healing nine years later on, is the outcome of one straightforward question that I had actually asked my mom's oncologist. Understanding what my mom will go through with the chemo treatment, radiation as well as the surgical procedure to remove her lung, I asked him what we had to do in our home from a nutritional aspect to assist the rough protocols she was about to start, he stated, "nutrition has nothing to do with cancer"! Wait a minute, what? And therein lies the problem with the entire system, the medical industry does not teach about health, they teach on "illness management". That declaration by my mom's oncologist launched me on my way to learn everything I could possibly learn regarding the body, just how cancer was created and how you can eliminate it. I saw my mother undergo those terrible therapies with her losing her hair and throwing up and ending up being weaker every day it drove me to find out every little nugget of information that could aid her. My mom made it through despite the treatments. Most individuals don't recognize that chemotherapy and radiation are carcinogenic. Simply put, they can create cancer all on their own. Cancer cells have a high recurrence rate and I needed to be ready if she ever needed to battle it again. All of my study brought me to Dr Thomas Lodi and An Oasis Of Healing. I knew precisely just what to do if cancer ever raised its ugly head once more. Use these additional search terms to find us on the internet as well; Dr Thomas Lodi Patient Story, Dr Thomas Lodi, Dr Thomas Lodi Patient Story Testimonial, Dr Thomas Lodi Patient Story Review, Dr Thomas Lodi Personal Patient Testimonial, Dr Thomas Lodi Patient Testimonial, Dr Thomas Lodi Patient Story Integrative Oncology, Dr Thomas Lodi Patient Story Metabolic Medicine, Dr Thomas Lodi Inspiring Patient Story, Dr Thomas Lodi Empowering Patient Story. https://www.youtube.com/playlist?list=PLgEvpazxx5NO6hb7a1M8pWbhr-jvWtIaX https://www.youtube.com/user/oasisofhealing/videos Disclaimer for An Oasis of Healing and Dr. Thomas Lodi videos: The content found here is for informational purposes only, and is in no way intended as medical advice, as a substitute for medical counseling, or as a treatment/cure for any disease or health condition and it should not be used as such. Always work with a physician before making any changes to prescription drugs or a qualified health professional before making any changes to your diet, lifestyle, or exercise activities. This information is provided as-is, and the reader/viewer assumes all risks from the use, non-use, or misuse of this information. Testimonials All diagnoses, recoveries and examples are only of what has been achieved by others, and such results are not typical. Where specific testimonials and treatments are used and attributed to a particular individual or business, those persons are sharing their actual experience and are in no way to imply or solicit a guarantee of projection of a cure, your medical condition or results.
TITLE: FDA Approval of KEYTRUDA for Treatment of Gastric Cancer GUEST: Dr. Charles S. Fuchs PRESENTER: Neal Howard OVERVIEW: Dr. Charles S. Fuchs discusses the recent FDA approval of KEYTRUDA (pembrolizumab) for patients with advanced gastric cancer that have received 2 or more lines of chemotherapy, and what this means for patients, doctors, and caregivers. For more information about this interview, visit this link: https://healthprofessionalradio.com.au/new-gastric-cancer-treatment/
Views: 226 Health Professional Radio
Medical oncologist Larry Norton, Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering, says that new information about how breast cancer cells behave is transforming our approach to treating the disease. Scientists have revealed that one of the dangers of breast cancer cells is their ability to recruit other cells that promote tumor growth and damage healthy tissue. This information has paved the way for research to develop new therapies that target and interfere with these cellular processes. Better understanding of the disease has also influenced the surgical management of breast cancer, resulting in less extensive operations.
Views: 1431 Memorial Sloan Kettering
Colon vs Rectal Cancer Colorectal cancer specialist Nancy Kemeny, MD, explains the differences between colon and rectal cancers. You start from the GI tract, you go into the esophagus, the stomach, the small bowel, and then you hit the colon. And at the very end of the colon is the rectum. So, in a sense, rectal cancer is worse, because it's very low, many times if it's really low, in order to remove it, the patient has to have a colostomy, which in the minds of many patients is a very bad thing. But for almost all colon cancers, you do not need a colostomy. So it's only the very low rectal cancers where that's needed, and also in the treatment, when you're talking about adjuvant treatment, which means the treatment after a section, the treatments will be different. Because in colon cancer, since it's higher up, and since it spreads in the abdomen, and to the liver and lungs, the treatment is chemotherapy afterwards. But in rectal cancer, since it's very low, and it's very close to the nerves and the bones and everything is very close to where the rectum is, you need radiation as well as chemotherapy after the surgery, or even before the surgery. A lot of surgeons these days like to do radiation and chemotherapy before the surgery to try to reduce the tumor, so they will have to do less surgery. So the treatments are different, depending on whether it's colon or rectum. But once it's metastatic, meaning that it's spread to the liver or lungs, or to the bones, then the treatment is the same.
Views: 720 Health News
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.
Views: 99 Targeted Oncology
CINCINNATI (WKRC) - A drug works with the body's own immune system to fight cancer and the latest clinical trials showed it appeared to be working to extend lives. At OHC in Cincinnati some of those trials were still open Thursday, June 16, and doctors treating patients, especially with lung cancer, said they were seeing remarkable results. When Tricia Stone, already a breast cancer survivor, was diagnosed with lung cancer more than four years ago Dr. Ed Crane initially started her on traditional treatment with chemotherapy. Stone said, "And that was going really well, for maybe a year and a half. And then the cancer, as Dr. Crane says, got angry and went to my esophagus, and then it went to my stomach." So Dr. Crane then began to look for other treatment options, "And fortunately we had the trial open up for Nivolumab. Which is now approved for use in patients." Nivolumab is a drug given by IV every two weeks. It's now in continued trials for long term use because it appears to work in patients in a unique way. While cancer cells in the body were usually able to camouflage against the body's immune system, this treatment takes away that camouflage so that their immune system identifies cells that really weren't supposed to be in the body. Dr. Crane said that it gave new hope to many of the patients that he treated. It was a newer way of thinking about cancer where patients were living longer with cancer and not dying from it. That was no doubt the case for Tricia Stone, "Yeah, because I've been here now for four and a half years and originally it was maybe six months." Tricia now gets regular follow up scans and officials said her cancer was under excellent control. The drug also was used in melanoma and it may have promise for other cancers too.
Views: 48 LOCAL 12
Dr. Ezra Cohen explains how head and neck cancer is categorized, current treatment options, and the latest research developments in this introductory patient education video. More Information Head and Neck Cancer: www.cancer.net/headneck
Views: 2128 Cancer.Net
Zydelig (Idelalisib) is an FDA approved targeted therapy cancer treatment for certain types of blood cancers that have relapsed, such as chronic lymphocytic leukemia. In this video, oncologist Dr. Stephen Lemon discusses how this treatment works and what types of side effects it may cause. Learn more about this treatment at http://www.oacancer.com/how-zydelig-idelalisib-treats-certain-blood-cancers/ Unlike a standard chemotherapy, targeted therapies like #Zydelig identify and attack cancer causing cells, while striving to cause less damage to healthy cells. Zydelig is developed by Gilead. Stephen Lemon MD is not affiliated with Gilead. These cancer education videos are produced to provide more information on new cancer treatments to patients and their families. Dr Stephen Lemon is medical oncologist who now practices at Overlake Cancer Center in Bellevue WA. He produces cancer information videos and web related cancer education projects. He invites you to follow his ongoing work at https://www.lightersideofcancer.com/
Views: 436 Oncology Associates
Lung cancer kills more men and more women than any other cancer in the world. Annually in the UK it causes 34,000 deaths. This is because unlike many other cancers, early warning signs are not detected. By the time the cancer is found it is often too late to save the patient. PDT Norfolk www.pdtnorfolk.co.uk is fundraising to sponsor research which will help change all this. This research, to be conducted by Dr Sam Janes of University College London's Lungs for Living Centre, will take the form of a major Clinical Trial using photodynamic therapy to destroy pre-cancerous lesions, the lesions that for many people lead to lung cancer. If the research proves that this treatment works -- and there is great promise that it will -- many people's lives will be saved in future.
Views: 1501 Tracy Island TV
AMAZING 7 RAW GARLIC BENEFITS FOR REVERSING DISEASE As you are about to see, raw garlic benefits are plentiful. It can used as an effective form of plant-based medicine in many ways, including the following. 1. Garlic for Heart Disease According to the Centers for Disease Control and Prevention, heart disease is the No. 1 killer in the United States, followed by cancer. (3) Garlic has been widely recognized as both a preventative agent and treatment of many cardiovascular and metabolic diseases, including atherosclerosis, hyperlipidemia, thrombosis, hypertension and diabetes. A scientific review of experimental and clinical studies of garlic benefits found that, overall, garlic consumption has significant cardioprotective effects in both animal and human studies. (4) Probably the most amazing characteristic of garlic is that it’s been shown to literally reverse early heart disease by reversing plaque buildup in arteries. A 2016 randomized, double-blind study published in the Journal of Nutrition involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome. The results of the study showed that aged garlic extract effectively reduced plaque in coronary arteries (the arteries supplying blood to the heart) for patients with metabolic syndrome. (5) One of the lead researchers, Matthew J. Budoff, M.D., said, “This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease. We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.” (6) 2. Garlic for Cancer Allium vegetables, especially garlic and onions, and their bioactive sulfur compounds are believed to have effects at each stage of cancer formation and affect many biological processes that modify cancer risk. (7) In the words of the NIH National Cancer Institute, “Several population studies show an association between increased intake of garlic and reduced risk of certain cancers, including cancers of the stomach, colon, esophagus, pancreas, and breast.” It also includes an answer to a very key question: How can garlic act to prevent cancer? The National Cancer Institute explains that “protective effects from garlic may arise from its antibacterial properties or from its ability to block the formation of cancer-causing substances, halt the activation of cancer-causing substances, enhance DNA repair, reduce cell proliferation, or induce cell death.” A French study of 345 breast cancer patients found that increased garlic, onion and fiber consumption were associated with a statistically significant reduction in breast cancer risk. (8) Another cancer that garlic has been specifically shown to positively affect is pancreatic cancer, one of the most deadly forms cancer. The good news is that scientific research has now shown that increased garlic consumption may reduce the risk of developing pancreatic cancer. A population-based study conducted in the San Francisco Bay area found that pancreatic cancer risk was 54 percent lower in people who ate larger amounts of garlic and onions compared with those who ate lower amounts. The study also showed that increasing the overall intake of vegetables and fruits may protect against developing pancreatic cancer. (9) Garlic also shows promise when it comes to treating cancer. Garlic’s organosulfur compounds, including DATS, DADS, ajoene, and S-allylmercaptocysteine (SAMC), have been found to induce cell cycle arrest when added to cancer cells during in vitro experiments. In addition, these sulfur compounds have been found to induce apoptosis (programmed cell death) when added to various cancer cell lines grown in culture. Taking liquid garlic extract and S-allylcysteine (SAC) orally has also been reported to increase cancer cell death in animal models of oral cancer. (10) Overall, garlic clearly show some real potential as a cancer-fighting food that should not be ignored or discounted. 3. Garlic for High Blood Pressure An interesting phenomenon of garlic is that has been shown to help control high blood pressure. One study looked at the effect of aged garlic extract as an adjunct treatment for people already taking antihypertensive medication yet still having uncontrolled hypertension. Garlic showed itself to be highly effective once again. The study, published in the scientific journal Maturitas, evaluated 50 people with “uncontrollable” blood pressure. It was uncovered that simply taking four capsules of aged garlic extract (960 milligrams) daily for three months caused blood pressure to drop by an average of 10 points. (11) Another study published in 2014 found that garlic has “the potential to lower BP in hypertensive individuals similarly to standard BP medication.
Views: 144 HEALTHY FOOD HOUSE
Interview conducted with Memorial Sloan Kettering Cancer Center's Dr. Bains, Dr. Gerdes and patient survivor Bart Frazzitta
Views: 306 Esophageal Cancer Education Foundation
Combining bariatric surgery with liver transplant shows promise for patients with medically-complicated obesity and end-stage liver failure, Mayo Clinic researchers recently reported in the American Journal of Transplantation. In a first-of-its-kind study led by Mayo Clinic liver transplant surgeon Julie Heimbach, M.D., the research seeks to identify solutions for a growing population of patients whose liver failure is either caused by or complicated by obesity. The prevalence of obesity in the U.S. is currently estimated to be approximately 35%. The obesity epidemic has also impacted patients with end-stage liver disease, and may be either the primary cause of their liver disease, or at least a contributing factor. Recent evidence has shown that nonalcoholic steatohepatitis (NASH) is the most rapidly rising indication for liver transplant in the U.S. and is predicted to become the most common indication. While obese patients can be transplanted with similar outcomes to non-obese patients in the short-term, the long-term impact of obesity on liver transplant patients post-transplant (including recurrence of NASH and hepatitis C) is becoming increasingly evident. Additionally, obesity is associated with diabetes, heart disease, and cancer which are leading causes of morbidity and mortality post-transplant. Obese patients are required to lose weight prior to transplant, and long-term outcomes are better if they can keep the weight off. Those who are successful with weight loss can proceed with a liver transplant as soon as a donor organ is available. Patients who are unsuccessful at weight loss are often denied for transplant until they lose weight. Mayo Clinic has devised a program which offers a combined liver transplant with sleeve gastrectomy for obese patients with end-stage liver disease who were unsuccessful in attaining weight loss in an aggressive noninvasive pre-transplant weight loss protocol. A sleeve gastrectomy is a bariatric weight loss procedure that is less complex than other gastric bypass procedures, and provides better absorption which is thought to be better for maintaining post-transplant immunosuppression levels. In a study of eight patients who met the criteria for the combined procedure, all of the patients and allografts survived. All of the patients had significant weight loss and none require insulin. None of the patients have had recurrence of liver disease. It did not increase operative time, and also prevented these patients from requiring two surgeries to complete the same goal. Dr. Heimbach describes the study and the procedure in this video .
Views: 802 Mayo Clinic
Immunotherapy uses the body’s immune system to fight cancer. This animation explains three types of immunotherapy used to treat cancer: nonspecific immune stimulation, T-cell transfer therapy, and immune checkpoint inhibitors. http://www.cancer.gov/immunotherapy
Views: 5162 National Cancer Institute
James P. Allison, PhD, has spent his career untangling the complexities of the human immune system and as a result of decades of research to understand the molecular mechanisms of T cells, has been a key leader in the translation of fundamental cancer science into innovative treatments with real benefits for patients. Learn more: www.AACR.org/Allison
Views: 1907 American Association for Cancer Research
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD, from the Melanoma Institute Australia, Sydney, Australia, discusses the opportunities and challenges of promising immunotherapeutic approaches for the treatment of patients with melanoma, including immune checkpoint inhibitors that target pathways related to T-cell activity.
Views: 63 European Medical Group
Targeted molecular therapy against egfr has shown promise as an adjuvant in head and neck squamous cell carcinoma (tcga, provisional)tcga carcinoma; Raw data at the nci of malignancies are carcinomas. Scc is the most majority of patients with head and neck cutaneous squamous cell carcinoma (cscc) are successfully treated surgical treatment primary site 29 jan 2015 cancer genome atlas profiled 279 carcinomas (hnsccs) to provide a comprehensive landscape mutations in ing1 gene (601566) have been found small but significant number cases neckHead genetics home reference. Head and neck squamous cell carcinomas. Treatment of advanced squamous cell carcinoma the head and neck cancer. The risk factors for development of cancers the oral cavity, my husband just finished his treatment stage 4a squamous cell head and neck cancer with unknown primary. Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. Targeted molecular therapy can also act as a complement to other existing cancer therapies. In europe the relative survival rate for head and neck cancer patients was 72. Squamous cell carcinomas of the head and neck ncbi nih. Squamous cell carcinoma of the head and neck ehns esmo squamous update on my husband was just diagnosed with overview treatment for cancer uptodate. Comprehensive genomic characterization of head and neck nature. These are the malignancies arising from mucosal lining of oral cavity, oropharynx, 20 nov 2016 in 2001, 500,000 cases head and neck squamous cell carcinoma (hnscc) were reported worldwide. Head and neck squamous cell head carcinoma (tcga, provisional). Head and neck squamous cell carcinoma wikipedia. Head and neck squamous cell carcinoma (hnscc) develops in the mucous membranes of mouth, nose, throat 12 oct 2002 cancer head is common worldwide (4. Head and neck cancer. Head and neck cancers are malignant neoplasms that arise in the head region which comprises nasal cavity, paranasal sinuses, oral salivary glands, symptoms different depending on where cancer started squamous cell carcinoma (scc) is most frequent tumor of. Googleusercontent search. This type of cancer begins in the flat squamous cells that make up thin layer tissue on 15 oct 1992 for patients with advanced, unresectable cell carcinoma head and neck, radiotherapy is standard treatment but has poor this chapter reviews carcinomas neck. Gov types head and neck fact sheet url? Q webcache. Head and neck cancers national cancer institute. Types of head and neck cancer understanding macmillan squamous cell carcinoma an overview. Hnscc is the sixth leading cancer by incidence worldwide most head and neck cancers are squamous cell carcinomas. Radiology reference high risk cutaneous squamous cell carcinoma of the head and neck. These squamous cell cancers are often referred to as carcinomas of the head and neck cells found in outer layer skin mucous membranes, which moist tissues that line body cavities such airways intestines. Cancer
Views: 63 Duck the Question
HOLLISTON, Mass., March 16, 2017 /PRNewswire/ -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it has promoted its Chief Medical Officer, Saverio La Francesca, M.D. to President. Dr. La Francesca has served as Chief Medical Officer of the Company since April 2014. Dr. La Francesca will continue to report to Biostage's Chief Executive Officer, Jim McGorry, as President and Chief Medical Officer. Dr. La Francesca is a cardiothoracic surgeon with extensive clinical experience committed to the clinical translation of transformative medical research. He has a unique combination of experience that features over 25 years of academic clinical surgical practice and innovative research, with a foundation in the cardiovascular, thoracic transplantation, cardiac assist device and regenerative medicine fields. Prior to joining Biostage management as Chief Medical Officer, Dr. La Francesca served in the Department of Cardiovascular Surgery and Transplantation at the DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation and where he was also the Director of the Ex-vivo Lung Perfusion Laboratory. Previously he was an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas and currently holds an appointment as Associate Professor of Surgery at the University of Rome "La Sapienza" in Rome, Italy. "Dr. La Francesca left a prominent heart and transplant practice to join Biostage because he wanted the opportunity to use his unique skills as a surgeon and researcher to bring an innovative technology to underserved patients. In recognition of Biostage's commitment to clinical development and the advancement of our Cellframe™ technology into humans, we are elevating Dr. La Francesca's responsibilities to more clearly align with our IND and clinical development activities," commented Jim McGorry, CEO of Biostage. "Dr. La Francesca deserves great credit for advancing our Cellframe technology across multiple indications. We look forward to reporting further progress on our IND and our pilot clinical study into humans in 2017." Biostage remains on track to file its IND application with the U.S. Food and Drug Administration (FDA) for adult esophageal cancer in the third quarter of 2017 and commence its first-in-human studies for its Cellspan esophageal implant before the end of 2017. As previously stated, in addition to developing its Cellspan esophageal implant for use in adults with esophageal cancer, the Company is evaluating its Cellspan esophageal implant for use to treat pediatric esophageal atresia (EA). EA is a rare birth defect in which a baby is born with a gap between the upper and lower esophagus, which effects about 1 in 2,500 babies in the U.S. Biostage remains extremely encouraged with its EA co-development efforts with Connecticut Children's Medical Center. The Company is also evaluating additional partnerships with children's hospitals showing strong interest in this program. Successful development of the Company's Cellframe™ technology in EA opens the opportunity for a pediatric voucher. Under Section 529 to the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA will award priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria. Under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The recently enacted 21st Century Cures Act reauthorized the rare pediatric disease priority review voucher along with additional favorable incentives to regenerative medicine companies. "During my three-year tenure at Biostage, I have led the development of the Cellframe Technology, leveraging our expertise in material science and bioengineering. I believe that the power of our regenerative approach has the potential to revolutionize the treatment paradigm in areas of significant unmet medical need. Given the extremely consistent and promising preclinical data obtained in our large animal model, we are now positioned to accelerate toward the clinic. I am excited to be leading our clinical effort along with our continued preclinical development. It is a privilege to be collaborating with world leading clinical institutions and I look forward to continue working with the team at Biostage to deliver on the promise of this groundbreaking technology," stated Dr. La Francesca
Views: 713 BGN - Blockchain Global News
In 2013 Shannon Semple of New Bern, North Carolina was diagnosed with thymic carcinoma, a rare cancer affecting fewer than 100 people in the U.S. each year. A series of failed treatments brought her to MedStar Georgetown in 2015 where she met Giuseppe Giaccone, MD, PhD who had initiated a clinical trial of pembrolizumab through the Georgetown Lombardi Comprehensive Cancer Center. See how Shannon is living with no evidence of active disease one year later. To learn more about immunotherapy or to make an appointment call 1-888-666-3432 or visit MedStarGeorgetowncancer.org.
Views: 3203 MedStar Georgetown University Hospital
There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a growing number of new and improved targeted agents and efficacious combination regimens yielding substantial clinical benefits in both early and late stages of the diseases. Moreover, breakthroughs in molecular profiling, cancer immunology, early stage detection, and novel diagnostic techniques have led to accelerated strides in GI cancer research and management. As the field of GI malignancies is continuously evolving, community oncologists must strive to keep abreast of the latest developments and resolve new issues in optimizing the management of esophageal, gastric, hepatocellular, pancreatic, and colorectal cancers. To this end, this webcast highlights the clinically significant information presented during the 2016 Great Debates and Updates in GI Malignancies in New York, New York from April 1-2, 2016. In this presentation, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
Views: 2968 ImedexCME
Visit www.goldensunrisenutraceutical.com to learn more.......... Esophageal cancer patient discusses his experience with a revolutionary new innovative discovery of KemoHerb. Part 2 of2 NFL Rusty Hilger quarterback.
Views: 1150 Golden Sunrise Nutraceutical